Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>The shares of Gland Pharma were trading 18% higher at ₹2,143 apiece on November 23 at 10:20 am. </li><li>The IPO has made its initial investors $1.05 billion richer in the past two days. </li><li>The experts believe that its strong financials have been the reason investors ignored its Chinese promoter.</li><li>While you may have missed the listing gains, the investment experts believe there are a lot more lies ahead for the <keyword id="10317201" type="UNKNOWN" weightage="20" keywordseo="Gland-pharma-investors">Gland Pharma investors</keyword>. </li></ul>The shares of Gland pharma are seeing a stellar demand from investors post the IPO listing. The IPO has made its initial investors 22% richer in the past two days — gaining over ₹7748 crore ($1.05 billion) since its debut to the current market capitalisation of ₹35,669 crore. <div type="image" title="Gland Pharma share (2)" msid="79363622" hostid="261"></div> Despite the muted response from investors during the initial public issue, the shares listed at a premium of 13% and closed 21% higher on the first day of the debut. And, the stocks were trading 18% higher at ₹2,143 apiece on November 23 at 10:20 am. This was the 13th company to list this year and the largest ever a public issue in the Indian pharma industry. The party may not be over yet! While you may have missed the listing gains, the investment experts believe there are a lot more lies ahead for the Gland Pharma investors. Chakri Lokapriya, CIO &amp; MD, TCG AMC <a href="https://economictimes.indiatimes.com/markets/expert-view/can-gland-pharma-stock-see-more-upside/articleshow/79338981.cms">told Economic Times</a>, that “the company’s profitability and growth are very reasonable. It has 45-50% of its revenue coming from a few large clients, and that does present some kind of concentration risk. But just the breadth of the business allows the company to continue to do well. I think there is still upside from the current levels for Gland Pharma.” <div type="image" title="Gland Pharma profit and revenue (2)" msid="79363627" hostid="261"></div> The experts believe that its strong financials have been the reason investors ignored its Chinese promoter. “The stock is trading above its midcap pharma peers but higher valuations justified by the last 3-year revenue growth and PAT growth of 27% and 55% CAGR respectively. Any dip in price can be a good opportunity for long-term investors,” said Yash Gupta, Equity Research Associate at Angel Broking. The company has its business spread over 60 countries and a great track record of revenue delivery and profitability across the United States, Europe, Canada, Australia, India and the rest of the world. Some of its top B2B clients include Sagent Pharmaceuticals and Apotex as well as Fresenius Kabi USA and Athenex Pharmaceutical Division in the United States and the rest of the world. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stock-movers-ril-future-retail-ujjivan-sfb-pfizer-cg-power-and-others/articleshow/79362432.cms" data-type="tilCustomLink">Top stock movers — RIL, Future Retail, Ujjivan SFB, Pfizer, CG Power, and others</a> <a href="https://www.businessinsider.in/tech/apps/news/how-to-earn-money-at-home-from-googles-task-mate/articleshow/79362215.cms" data-type="tilCustomLink">Google is testing ‘Task Mate’ in India, which lets users earn money for doing tasks on their smartphones</a>

Gland Pharma IPO investors made more than a billion dollars in just 2 days

<ul><li>Gland Pharma, which debuted on the share market last year, has doubled its share price in a little over 6 months.</li><li>The IPO priced at ₹1,500 was subscribed twice over and the stock listed at a 20% premium to the issue price.</li><li>In the last three months alone, the company’s shares have surged by over 44%.</li></ul>Investors who stuck with Gland Pharma despite the ₹6,480 crore initial public offer (IPO) receiving a tepid response have reason to celebrate – their initial investment has doubled in a span of a little over 6 months. Shares of the pharma company rallied on May 18, surging by nearly 8%. The <keyword id="10219475" type="UNKNOWN" weightage="20" keywordseo="Gland-Pharma-share-price">Gland Pharma share price</keyword> was hovering around ₹3,011 at 11:00 am, more than ₹200 up from its previous closing price of ₹2,793. <div type="image" title="Gland Pharma 20_11_20 to 18_05_21." msid="82732400" hostid="261" caption="&amp;lt;p&amp;gt;Gland Pharma share price&amp;lt;/p&amp;gt;"></div> Gland Pharma was listed on the stock exchanges on November 20, 2020. Compared to the issue price of ₹1,500, this is a 100% gain till date. Nearly half of the surge in Gland Pharma’s shares has come after the slump on February 1 – since then, the share price has increased by over 44% till date. May alone has contributed to a 14% increase in the share price of the company, in the run up to its March 2021 quarter results. As a result of this rally, Gland Pharma’s total market capitalisation has crossed ₹45,000 crore. And there could be a further rally. “Gland Pharma reported a good set of numbers in Q4FY21, with good revenue growth in export as well as domestic market,” said a report by Angel Broking, adding that the company is capitalising on the demand for COVID-19 related products. A report by Kotak Institutional Equities Research highlighted the positives that outline Gland Pharma’s growth prospects. “Gland Pharma ended FY2021 on a strong note with new launches and expansion into other geographies driving robust revenue growth. A strong pipeline of products, healthy filing rate, entry into new markets, potential for increasing market share in recently launched products along with higher traction in Covid-related products provide solid medium-term growth visibility,” the report said. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 1pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Brokerage </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 1pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Target price </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 1pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Upside </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 1pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 1pt;vertical-align:bottom;background-color:#d9d9d9;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Motilal Oswal </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 1pt;vertical-align:bottom;background-color:#d9d9d9;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">₹3280 </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 1pt;vertical-align:bottom;background-color:#d9d9d9;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">9% </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 1pt;vertical-align:bottom;background-color:#d9d9d9;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">BUY </td></tr><tr><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">Share Khan </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">₹3040 </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.5pt;border-right:solid #000000 0.5pt;border-bottom:solid #000000 0.5pt;border-top:solid #000000 0.5pt;vertical-align:bottom;padding:0pt 5.75pt 0pt 5.75pt;overflow:hidden;overflow-wrap:break-word;">BUY </td></tr></tbody></table> “Our ability to respond to changing market demands during COVID-19 was visible bearing the registered growth in markets of the U.S, Europe, Canada and Australia and back of new launches and volume growth in existing portfolio, supported by our increased capacity,” said Srinivas Sadu, chief executive at Gland Pharma. However, there are some concerns that could impact the company’s performance, so there could be wisdom in being cautious. “The company’s profitability and growth are very reasonable. It has 45-50% of its revenue coming from a few large clients, and that does present some kind of concentration risk. But just the breadth of the business allows the company to continue to do well,” Chakri Lokapriya, managing director at TCG Asset Management, <a href="https://economictimes.indiatimes.com/markets/expert-view/can-gland-pharma-stock-see-more-upside/articleshow/79338981.cms">told Economic Times</a> after Gland Pharma’s IPO last year. SEE ALSO: <a href="https://www.businessinsider.in/business/telecom/news/airtels-india-business-is-back-in-the-black-after-a-very-long-time/articleshow/82709100.cms">Airtel's India business is back in the black after a very long time</a> <a href="https://www.businessinsider.in/business/telecom/news/mukesh-ambanis-reliance-jio-is-making-less-money-off-its-subscribers-than-it-did-12-months-ago/articleshow/82331233.cms">Reliance Jio is making less money off its subscribers than it did 12 months ago</a> <a href="https://www.businessinsider.in/tech/apps/news/whatsapp-responds-to-privacy-criticism-by-alleging-other-apps-like-zomato-ola-aarogya-setu-zoom-google-and-other-apps/articleshow/82570897.cms">WhatsApp responds to privacy criticism by alleging that other apps and tech companies also show disdain for user privacy</a>

A super hit IPO from 2020 has finally doubled investors' money

<ul><li>The 30-share BSE index was trading 0.34% higher, and the broader NSE Nifty was trading points 39 higher on Friday at 10:40 am. </li><li>Here’s a list of the top losers and gainers in the Nifty pack. </li><li>These are the top stocks that are buzzing in trade today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian equity benchmark indices surged in early trade on Friday, tracking gains in index-heavyweights HDFC twins, Kotak Bank and Bajaj Finance amid largely positive cues from global markets and sustained foreign fund inflow. The 30-share BSE index was trading 0.34% higher, and the broader NSE Nifty was trading points 39 higher on Friday at 10:40 am. Here’s a list of the top losers and gainers in the Nifty pack. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Gainers </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Losers </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Bajaj Finserv </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">IndusInd Bank </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Titan </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">RIL </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Nestle India </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">UPL </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tech Mahindra </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Axis Bank </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">NTPC </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">ICICI Bank </td></tr></tbody></table>*as of November 20, 10:35 am These are the top stocks in news today. <keyword id="6358032" type="CITY" weightage="20" keywordseo="SpiceJet">SpiceJet</keyword> extends gain for the second day SpiceJet shares gained over 5% — extending gains for the second day in a row after the US FAA cleared Boeing’s 737 Max aircraft to resume flying. 737 Max aircraft were banned nearly two years ago after two fatal crashes. SpiceJet has a fleet of 13 such planes that were grounded in March 2019. <keyword id="1553175" type="COMPANY" weightage="20" keywordseo="Vodafone-Idea">Vodafone Idea</keyword> gains nearly 5% The shares of Vodafone Idea soared 5% after receiving cash consideration of ₹3,760.1 crore for its 11.15% shareholding in Indus, post the completion of the much-delayed merger of Bharti Infratel and Indus Towers on Thursday. Mphasis up nearly 3% The shares of IT firm Mphasis gained over nearly 3% after its subsidiary, Mphasis Consulting, acquired UK-based Datalytyx for up to £13.3 million (about ₹130.4 crore). The acquisition is expected to provide access to strengthen Mphasis next-generation Data GTM Strategy and provide higher value partnership status with Snowflake and Talend for cloud-based data services, a regulatory filing said. <keyword id="6444828" type="ORGANIZATION" weightage="20" keywordseo="gland-pharma">Gland Pharma</keyword> stellar debut The shares of Gland Pharma listed at a premium of 12% over the issue price band on the Indian stock exchanges. The shares gained nearly 7% post listing, in minutes after debut. <keyword id="6425802" type="COMPANY" weightage="20" keywordseo="bharat-electronics">Bharat Electronics</keyword> surges 5% The shares of Bharat Electronics surged 5% post strong management guidance and brokerages remain bullish on the stock. Jefferies has maintained its “buy” rating with a target of ₹130 per share. SEE ALSO: <a href="https://www.businessinsider.in/tech/apps/news/pubg-mobile-india-was-supposed-to-launch-today/articleshow/79315462.cms" data-type="tilCustomLink">PUBG Mobile India was rumoured to launch today — but there is no official update from the company</a> <a href="https://www.businessinsider.in/stock-market/news/gland-pharma-shares-list-at-premium-of-12-records-stellar-debut-despite-the-slow-subscription-numbers/articleshow/79315924.cms" data-type="tilCustomLink">FOMO helps Gland Pharma swell on debut</a>

Top stock movers — RIL, SpiceJet, Titan, Tech Mahindra, Vodafone Idea, Gland Pharma, Bharat Electronics, and others

<ul><li><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div></div></div>The effectiveness of <a href="http://markets.businessinsider.com/stock/Mallinckrodt-Quote">Mallinckrodt Pharmaceuticals</a>' blockbuster drug H.P. Acthar over cheaper alternatives is being questioned by an Oregon State University study.</li><li>The drug is prescribed by a small number of doctors, and many of them received speaker fees from Mallinckrodt.</li><li>Mallinckrodt depends on Medicare for nearly half of Acthar sales, raising a risk for investors. President Donald Trump has proposed allowing Medicare to negotiate prices.</li><li>Mallinckrodt is conducting studies to demonstrate Acthar's effectiveness.</li></ul>Tell me if this makes sense to you.In 2015 the US government <a href="http://www.businessinsider.com/achtar-drug-shows-flaws-in-drug-pricing-payment-system-2017-2">spent over half a billion dollars</a> on a <a href="https://www.goodrx.com/h.p.-acthar">$38,000</a> non-lifesaving drug with a wide range of cheaper alternatives, making it one of the top 20 expenses for Medicare Part D, a prescription drug program.What's more, according to a study by doctors at Oregon State University, this drug is prescribed by less than 1% of doctors in the US. The drug is called H.P. Acthar, and it is a blockbuster for <a href="http://markets.businessinsider.com/stock/Mallinckrodt-Quote">Mallinckrodt Pharmaceuticals</a>, the company that acquired it in 2014. But it is also old enough that it never went through the clinical trials the government requires of a new drug today. Its main use is to treat infantile spasms, but Medicare - a program for the elderly - spent $504 million on it because it is also prescribed as a treatment for 18 other diseases, including multiple sclerosis.What caught the attention of researchers at Oregon State was how much more expensive the government-subsidized Acthar was than some of its competitors - sometimes tens of thousands of dollars more. The researchers wanted to know why such a small number of doctors had come to prescribe such a costly drug to sick adults. Their study is offering fresh ammunition for <a href="http://www.businessinsider.com/achtar-drug-shows-flaws-in-drug-pricing-payment-system-2017-2">critics of Mallinckrodt and its model for Acthar.</a>Those critics include short sellers who are profiting as Mallinckrodt's shares get crushed. <h2>'Who are these people?'</h2>There are some explanations for why the prescriptions could be concentrated among a small number of doctors. Acthar is used only by specialists, and Mallinckrodt says it's a third- or fourth-line treatment, meaning patients using it have tried other options (and perhaps have sought out the doctors willing to prescribe it). <div class="KonaFilter image-container display-table float_left"><div><div class="image on-image"></div></div></div>The researchers who looked into it don't find this or other explanations convincing justifications for the expense to the government.The study into Acthar prescriptions was conducted by Dennis Bourdette, the chair of neurology in the Oregon Health and <keyword id="41551" type="ENTERTAINMENT" weightage="60" keywordseo="science">Science</keyword> University School of Medicine, and Daniel Hartung, an associate professor in OSU's College of Pharmacy."The list of indications from the FDA are infantile spasms, multiple sclerosis, and then all these other indications that the neurologist and rheumatologist prescribe it for," Bourdette told Business Insider. "There have never been any designed controlled trials or any basis that show that it's superior to synthetic steroids, which brings up the question - who are these people and why are they prescribing this when we have synthetic steroids that work?"<h2>Dosage question</h2>Since Mallinckrodt purchased the drug in 2014, the drug's sale to Medicare Part D patients has exploded. The $504 million the program spent on the drug in 2015 was up from $263 million in 2013, and the increase seems to have come from a jump in the number of doses per patient, <a href="https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Dashboard/2015-Medicare-Drug-Spending/medicare-drug-spending-dashboard-2015-data.html">government data shows</a>. <div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div></div></div>While just more than 3,100 Medicare Part D users take the drug, the amount of the drug they're taking is steadily increasing.Acthar patients were getting about 23.7 units each in 2015, according to the most recently available government data. In 2013, about 2,400 Medicare Part D users were taking the drug, and they were getting 17.5 units on average.This is way over the dosage guidelines that the <a href="http://www.acthar.com/pdf/acthar-pi.pdf">prescription information</a> for Acthar suggests. Bourdette said most patients should be getting only a handful of doses.We also asked Bourdette, though, whether the doctors who were prescribing Acthar heavily were simply big on prescribing drugs across the board. He disputed that idea, too."According to the Medicare database these doctors do tend to prescribe more medications," Bourdette said. "But that doesn't explain Acthar because when it comes to Acthar they're prescribing 100-fold more."<h2>Age before efficacy</h2>Acthar was basically grandfathered into approval by the US Food and Drug Administration because the government didn't require clinical trials the way it does today when the drug was brought to market back in 1952.Now it's classified as an "<a href="https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm">orphan drug</a>" - a drug that treats rare diseases that affect fewer than 200,000 people in the country - but Mallinckrodt bought it with the intention of expanding its use."Mallinckrodt's goal has been - and continues to be - to acquire under-resourced, under-utilized products like H.P. Acthar Gel, which are utilized in areas of high unmet medical need, typically in narrow patient populations, and then for Mallinckrodt to invest significantly in those products," a representative for the company told Business Insider in an email. "The Company invests by building an even larger body of evidence to demonstrate which patients can benefit most from the drug and shares that information with physicians and payers to ensure those patients can get access to the product."<div class="KonaFilter image-container display-table float_left"><div><div class="image on-image"></div></div></div>These tactics have come under fire since 2015, when the 5,000% price increase of an AIDS-related treatment called Daraprim - by a tiny firm run by a former hedge fund manager named Martin Shkreli - shocked the US public.Mallinckrodt knew what it was getting into with Acthar before it bought it. Like Daraprim, its price has been hiked substantially - to $38,000 from as little as $1,650 before 2007, something that made the drug the target of a <a href="http://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html">New York Times profile</a> that raised questions about its efficacy and noted that at least one major insurer - Aetna - was unwilling to pay for it to treat anything but infantile spasms.Scrutiny of drug pricing and orphan drugs is far more intense now than it was in 2012, and it has come from lawmakers including President Donald Trump, who has suggested that Medicare should negotiate with drugmakers, and Sen. Chuck Grassley, an Iowa Republican who is looking into the orphan drugs and their privileged status.That is why the investors who previously loved companies that bought old drugs and jacked up their prices are fleeing this business model.<h2>'Marketing ploy'</h2>Mallinckrodt and Acthar's previous owner, Questcore, have yet to produce any studies showing that Acthar is superior to its cheaper alternatives. In the case of MS, that alternative is methylprednisolone, an intravenous treatment that cost $1,000 to $2,000 as opposed to Acthar's $40,000.The Mallinckrodt representative told Business Insider that the low number of physicians prescribing Acthar was "proportional" to the roughly 9,000 people who take it as a third- or fourth-line treatment when other medications fail. The person said that number "is growing as Mallinckrodt continues to generate data and introduce it to a whole new generation of physicians."Bourdette doesn't buy that. Whether Acthar is a second-, third-, or fourth-line therapy, he still doesn't see why the drug should cost so much or be as widely used as it is."If they're using it to treat relapses, you would be an incredibly rare patient," he said in a phone call with Business Insider. "If you've got somebody resistant to steroids, there are so many more noncortical therapies."Mallinckrodt, which has only owned Acthar for a little over two years, is conducting four company-sponsored controlled trials related to the drug's efficacy. Details on the studies, however, reveal that only one of them compares Acthar to alternative treatments.Bourdette is skepical of such phase four (post-FDA-approval) trials anyway. In the past some companies have used them to entice doctors to use their product, and doctors can even make a profit off of the studies if they're designed to come in under cost.In these cases, Bourdette said: "It's not really a scientific research study - it's a marketing ploy."<h2>Paid speakers</h2>Mallinckrodt, like a lot of other drug companies, also <a href="https://www.mallinckrodtspeakerbureau.com/Account/LogOn?ReturnUrl=%2f">has a speakers program</a> through which it can book and pay doctors to talk about its drugs.Typically, the top prescribers of Acthar not only have received payments from Mallinckrodt but also "are typically getting larger payments from companies that are developing disease-modifying therapies," Bourdette told us.Business Insider reached out to the top 10 prescribers of Acthar, but they either did not respond to our requests for comment or would not comment on the drug.One of these doctors is Robert Baughman, a professor of internal medicine at the University of Cincinnati who is <a href="https://clinicaltrials.gov/ct2/show/results/NCT02188017">collaborating with Mallinckrodt on a study</a> on Acthar's efficacy curing patients with sarcoidosis, a disease that affects the lungs and lymph glands. This is part of the "investigator-initiated research," which Mallinckrodt supports financially through grants.Based on his prescription behavior, Baughman clearly believes in the drug. He was the third-most-frequent <a href="https://projects.propublica.org/checkup/drugs/8004">prescriber of Acthar back in 2014</a>, ProPublica's prescriber database shows. He has also received $21,625 for promoting Acthar from 2013 to 2015 (that's out of $116,000 for speaking and promotion fees for drugs during that period)."Thanks for offer, but will have to say no," he said via email when we asked him to speak about the drug.That said, <a href="https://www.ncbi.nlm.nih.gov/pubmed/26626451">what he's published about Acthar</a> is not encouraging. Of 47 patients, 18 discontinued the program because of "cost (four patients), death (two patients), or drug toxicity (eleven patients), or noncompliance (1 patient)."Only 11 of the 29 remaining patients saw some improvement in one or more organs after taking Acthar for three months.Another top prescriber who does think Acthar is effective is Regina Berkovich, an assistant professor of clinical neurology at the University of Southern California. She published a paper back in 2013 arguing that Acthar was a good <a href="http://www.pri-med.com/DigitalAssets/Shared%20Files/Syllabus%20Files%20Spring%202013/C&amp;E/West/Track%201-Session%203_MS_Updates-West_ONLINE.pdf">second-stage treatment for multiple sclerosis</a>.That same year she accepted $23,895 for talking about Acthar. That's out of $142,978 in speaking and other fees she collected that year.The top prescriber of Acthar (making up 1% of all prescriptions) is an Ohio rheumatologist named David Mandel. He also did not respond to Business Insider's request for comment on the drug, and Acthar does not appear on his website's "<a href="http://dmandelmd.com/ground-breaking-therapies/">treatments</a>" page, though its competitor Humira does. From 2013 to 2015, Mandel has received $22,762 in speaking and other fees from Mallinckrodt for promoting Acthar, according to government disclosures.<h2>Risk management</h2>Speaker programs are turning into a new kind of risk for investors as they come under scrutiny by federal officials around the US.Last year Salix, a pharmaceutical firm purchased by Valeant in 2015, paid a <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwi3xtaSotTSAhVJwGMKHTJzCkgQFggaMAA&amp;url=https%3A%2F%2Fwww.justice.gov%2Fusao-sdny%2Fpr%2Fmanhattan-us-attorney-announces-54-million-settlement-against-salix-pharmaceuticals&amp;usg=AFQjCNG1pkkTWDaTSRYpXRHnrA5_OsuTZg&amp;sig2=EiJZStoo2vwFxH1TA2EuCw&amp;bvm=bv.149397726,d.amc">$54 million settlement to the Justice Department</a> over its speakers program. Specifically, it was accused of using the programs "as a mechanism to pay kickbacks to doctors to induce them to prescribe SALIX drugs and medical devices that were reimbursed by federal healthcare programs." Forest Laboratories paid a<a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=2&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwi3xtaSotTSAhVJwGMKHTJzCkgQFgggMAE&amp;url=https%3A%2F%2Fwww.justice.gov%2Fopa%2Fpr%2Fforest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations&amp;usg=AFQjCNHwJmXQBcYRYd8bNwwJI_7xsHK6Sw&amp;sig2=jOuu5vc4GYSCG1Sh8UF4uw&amp;bvm=bv.149397726,d.amc"> $38 million fine</a> for a similar offense.And two Alabama doctors now <a href="http://www.al.com/news/mobile/index.ssf/2017/02/mobile_doctors_found_guilty_in.html">face up to 20 years in prison for running an opioid</a> "pill mill" out of their two Mobile clinics. They were discovered, in part, because back in February of last year a sales rep for Insys Therapeutics, the company that makes the powerful opioid fentanyl, admitted to paying them illegal kickbacks disguised as speaker fees.Nobody is suggesting that Mallinckrodt is doing anything wrong. The company representative reiterated that the company's speaker program was "designed to be consistent with applicable legal and regulatory requirements, the PhRMA Code and industry best practices," referring to the drug-industry lobby.And Mallinckrodt does acknowledge that the fact that its drug hasn't been tested is a danger to its business."Clinical trials demonstrating the efficacy for Acthar are limited," the company wrote in its annual report. "The absence of such clinical trial data could cause physicians not to prescribe Acthar, which could negatively impact our business, financial condition, results of operations and cash flows."Until the drug has been tested against cheaper alternatives, and until the results of any such tests are published, investors, legislators and doctors will remain skeptical of Acthar's price tag and the system that allows for it. <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/white-marks-on-nails-health-2017-3">Here's what those white marks on your nails say about your health</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="E5Njg3YTE6C6pYa0VSWutGEM6ff88xwu" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

Something weird's going on with the doctors prescribing one of pharma's most controversial blockbuster drugs

<div class="KonaFilter image-container display-table"><div><div class="image on-image">REUTERS/Stefan WermuthGene and cell therapies are taking off.</div></div></div><ul class="summary-list"><li>The hottest <a href="https://www.businessinsider.com/fda-cber-director-peter-marks-on-developing-rare-disease-gene-therapies-2019-3">new area of medicine</a> today is a cutting-edge technology that leverages the body's own cells to treat disease. </li><li>Companies have been pouring in and <a href="https://www.businessinsider.com/avexis-sma-gene-therapy-manufacturing-drove-9-billion-novartis-deal-2019-3">investing billions</a>. But they're encountering one big challenge: actually making the treatments. </li><li>New gene and cell therapies are encountering years-long backlogs, and delays keep potentially <a href="https://www.businessinsider.com/stanford-ethicist-on-bill-gates-worries-about-gene-therapy-2019-3">lifesaving medicines</a> away from patients.</li><li><div dir="ltr"><a href="https://www.businessinsider.com/?hprecirc-bullet">Visit BusinessInsider.com for more stories.</a></div></li></ul>For the biotech company <a href="https://meiragtx.com/company/board-of-directors/#bod-data-lg-2">Meira Gtx,</a> a 29,000-square-foot factory in central London is the solution to a problem that has bedeviled its entire industry.The $660 million startup develops cutting-edge gene therapies, which tinker with the <a href="https://www.businessinsider.com/gene-therapy-treats-disease-but-prices-could-strain-us-health-system-2019-2">body's DNA</a> in hopes of treating serious illnesses. Meira focuses on a number of diseases of the eye, salivary gland and brain. The company had only just started in 2015 when a huge opportunity opened up, to lease a drug <a href="https://meiragtx.com/our-strategy/manufacturing/">manufacturing facility</a> from a leading UK eye hospital. Meira jumped at it, quickly hiring pharma veterans to build out its capabilities and take over manufacturing, snapping up its new head of quality from the Swiss drug giant <a href="https://www.businessinsider.com/avexis-sma-gene-therapy-manufacturing-drove-9-billion-novartis-deal-2019-3">Novartis</a>. Gene therapy is the <a href="https://www.businessinsider.com/fda-cber-director-peter-marks-on-developing-rare-disease-gene-therapies-2019-3">hottest area in medicine,</a> offering up the potential to treat or even cure devastating rare and not-so-rare diseases. Gene therapy and a sister field, cell therapy, attracted more than <a href="https://alliancerm.org/publication/2018-annual-report/">$13 billion</a> in global financing last year, by an industry group's count. Some products have already been <a href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm">approved</a> in the US, and many more are in the works, with more than <a href="https://alliancerm.org/publication/2018-annual-report/">1,000</a> research trials ongoing. But first, companies have to <a href="https://www.businessinsider.com/avexis-sma-gene-therapy-manufacturing-drove-9-billion-novartis-deal-2019-3">make the medicines.</a> In a field so new, trendy, and intensely complicated, manufacturing has become a crucial, costly and time-consuming challenge, with a surge of new interest forcing biopharmaceutical companies to either build their own multimillion-dollar facilities or else wait on lines for years for others to manufacture them. Meira's enviable capability has sparked requests from other companies to make their products. And it could well explain an up to <a href="https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-janssen-develop-and">$440 million partnership</a> the biotech inked with Johnson &amp; Johnson's Janssen earlier this year, focused on both research and improving manufacturing."Manufacturing is critical to us," <a href="https://www.linkedin.com/in/zandyforbes/">Alexandria Forbes</a>, Meira Gtx's president and CEO, said in an interview with Business Insider. "It's an industry-wide issue." The biotech deliberately focused on disease areas where it wouldn't need to make huge amounts of the product, Forbes said. But other companies are facing the challenge on a much bigger scale."If you don't control your manufacturing, you don't control your fate," <a href="https://genetherapy-conference.com/">said</a> <a href="https://www.linkedin.com/in/katherine-high-b50baab1/">Katherine High</a>, Spark Therapeutics' co-founder, president and chief scientific officer, speaking at the <a href="http://genetherapy-conference.com">Gene Therapy for Rare Disorders</a> conference in Boston, Massachusetts last month. Spark is currently being acquired by Swiss drug giant Roche for <a href="https://www.businessinsider.com/how-roche-bought-biotech-spark-therapeutics-for-48-billion-2019-3">nearly $5 billion</a>.The challenge has also prompted deals among third-party companies that manufacture gene therapies, including one this week. On Sunday, <a href="https://www.wsj.com/articles/contract-drug-manufacturer-catalent-to-buy-paragon-bioservices-in-1-2-billion-deal-11555277951?shareToken=stf73c9092566048f38a5dbee281dbbaf2">The Wall Street Journal</a> reported that the manufacturer Catalent is buying privately-held Paragon Bioservices in an all-cash deal for $1.2 billion. Read more: <a href="https://www.businessinsider.com/spark-bluebird-avexis-executives-on-safety-for-gene-therapy-companies-2019-3">Billions of dollars are pouring into gene-therapy startups. Top execs at 3 companies described the biggest challenge the new field faces.</a><h2>Bottlenecks, backlogs, and millions of dollars in the balance</h2><a href="https://www.linkedin.com/in/tony-khoury-7470755/">Tony Khoury</a>, vice president of client and technical services at the consulting firm <a href="https://projectfarma.com/">Project Farma</a>, turns to an analogy to explain why it's so hard for companies to make gene therapies.Imagine you're a successful home baker, turning out dozens of warm cookies each weekend for friends and family to enjoy. To put out 12,000 cookies instead, your homegrown operation, with its little mixing bowl and standard apartment oven, would need to change dramatically.Except in gene therapy, you can't just multiply the recipe.Companies are working with viruses or living cells, so "it's not an exact <keyword id="41551" type="ENTERTAINMENT" weightage="100" keywordseo="science">science</keyword>" in the same way, he said.Whether companies are vying for slots at the contract manufacturing organizations (CMOs) that make the very specialized medicines, or trying to build their own factories, manufacturing has become a bottleneck for companies.Both routes are expensive. Hiring an outside organization can run in the neighborhood of $7.4 million just to get to the point where a company is able to test its products in humans, while doing the work in-house can come to about twice that, or $14.7 million, <a href="https://www.mustangbio.com/">Mustang Bio </a>Chief Technology Officer <a href="https://www.linkedin.com/in/knutniss/">Knut Niss</a> estimates.It's better to choose the in-house route if a company is doing a lot of manufacturing and research, Niss said last month at the Boston gene therapy conference.Read more: <a href="https://www.businessinsider.com/fda-cber-director-peter-marks-on-developing-rare-disease-gene-therapies-2019-3">The FDA's top official overseeing gene therapy had these 5 suggestions for startups flooding into the billion-dollar industry</a>Companies are also encountering long wait times to get their products made or to buy the requisite, ultra-specialized equipment."When everyone decides to order 600 hyperstacks, you can suddenly have some challenges. And some of us have experienced that," said <a href="https://www.linkedin.com/in/chriskmurphy/">Christopher Murphy</a>, chief operations officer at Brammer Bio, which is being acquired by Thermo Fisher for about <a href="http://thermofisher.mediaroom.com/2019-03-24-Thermo-Fisher-Scientific-to-Acquire-Brammer-Bio-a-Leader-in-Viral-Vector-Manufacturing">$1.7 billion</a> in cash.Murphy was referring to an essential piece of <a href="https://bioprocessintl.com/bioprocess-insider/hyperstack-shortage-caused-by-gene-therapy-surge/">equipment</a> employed in gene and cell therapy manufacturing.With any delay, lifesaving medicine is on the line. On one collaboration Project Farma did <a href="https://www.businessinsider.com/avexis-sma-gene-therapy-manufacturing-drove-9-billion-novartis-deal-2019-3">with Novartis's AveXis,</a> delays of even a day mean that "hundreds of babies are potentially not going to have the ability to get this treatment," Khoury said. "The queue in contract manufacturing is actually slowing down investigating these therapies and getting these therapies to patients," said the US Food and Drug Administration's <a href="https://www.businessinsider.com/fda-cber-director-peter-marks-on-developing-rare-disease-gene-therapies-2019-3">top official overseeing gene therapy</a>, Dr. <a href="https://www.fda.gov/AboutFDA/CentersOffices/ucm481936.htm">Peter Marks</a>. <h2>A field pioneered by academics 'then had to work backwards'</h2>It wasn't always obvious that treating disease at the genetic level would even be possible. Two decades ago, at least one high-profile <a href="https://abcnews.go.com/Health/story?id=3421869&amp;page=1">patient death</a> in a research trial of a gene therapy prompted skittishness from companies and investors. Pioneering work by university researchers ultimately powered the field's success today. But that background has contributed to its struggles, too. Once the data was promising, researchers "then had to work backwards, figuring out the manufacturing and controls," said <a href="https://www.linkedin.com/in/brian-kaspar-ba8b0ba/">Brian Kaspar</a>, chief scientific officer of Novartis's AveXis, who was one of those researchers before he joined industry.AveXis has invested heavily in its manufacturing capacity, which it has long seen as <a href="https://www.businessinsider.com/avexis-sma-gene-therapy-manufacturing-drove-9-billion-novartis-deal-2019-3">crucial for its future,</a> Kaspar said.Manufacturing is such a broad problem that industry group <a href="https://alliancerm.org">Alliance for Regenerative Medicine</a> (ARM) is working on a how-to guide spelling out the process, which it's calling "A-Gene."The group was also motivated by recent history. A group of drugs known as monoclobal antibodies, which fight cancer and treat conditions like rheumatoid arthritis, are now among the world's top-selling treatments. But when the drugs first hit the market, pharma companies encountered complex <a href="https://www.ncbi.nlm.nih.gov/pubmed/19234897">manufacturing challenges</a>, limiting how many could be made and making those that could be manufactured more costly. Using a model from that time as a guide, ARM started "A-Gene" in May of last year. Many companies have been involved in the effort, and the group expects to hammer out a draft by the end of the year.<h2>'For 10,000 patients, that means 10,000 batches'</h2>Around the world, 300,000 to 400,000 people are born with sickle cell disease, an inherited blood disorder that causes <a href="https://www.marketwatch.com/story/this-could-be-the-next-1-billion-drug-if-patients-get-on-board-2018-02-26">serious pain episodes</a> and can lead to an early death. The biotech Bluebird Bio believes its new experimental treatment <a href="https://www.businessinsider.com/biotech-bluebird-bio-suggests-installment-plan-for-gene-therapy-lentiglobin-2019-1">LentiGlobin</a> could make a big difference for those who have sickle cell disease.Read: <a href="https://www.businessinsider.com/biotech-bluebird-bio-suggests-installment-plan-for-gene-therapy-lentiglobin-2019-1">A biotech is proposing a plan to pay for its pricey rare-disease treatment the same way you'd buy a TV or dishwasher. Here's the inside story.</a>But developing LentiGlobin hasn't been easy. Bluebird Chief Technology and Manufacturing Officer <a href="https://www.linkedin.com/in/derek-adams-16793b4/">Derek Adams</a> calls it "the most complicated process I've ever seen."LentiGlobin entails taking a patient's blood plasma, modifying those cells outside of the body, and then re-introducing them into the patient by way of an infusion. Manufacturing gene or cell therapies can thus be a highly individualized, bespoke process, more like a one-of-a-kind boutique than a mass-market chain of stores."The patient starts the manufacturing process. That whole manufacturing process centers around the patient," Adams said at the Boston gene therapy conference. "That doesn't seem so bad until you realize that if you want to do this for 10,000 patients, that means 10,000 batches." <div class="margin-top"> <h3>NOW WATCH: <a href="https://www.businessinsider.com/spacex-falcon-heavy-elon-musk-second-launch-video-2019-4">Watch SpaceX launch and land Falcon Heavy, the world's most powerful rocket</a></h3> <div> </div> </div>

You Searched For "Gland pharma Buy" and got 5 results

Gland Pharma IPO investors made more than a billion dollars in just 2 days

Navdeep Yadav

A super hit IPO from 2020 has finally doubled investors' money

Rounak Jain

Top stock movers — RIL, SpiceJet, Titan, Tech Mahindra, Vodafone Idea, Gland Pharma, Bharat Electronics, and others

Navdeep Yadav

Something weird's going on with the doctors prescribing one of pharma's most controversial blockbuster drugs

Linette Lopez

'This is the most complicated process I've ever seen': As billions flow into the hottest new area of medicine, top execs say a crisis is brewing

Emma Court

Popular Keywords

Buying Guides